Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Paediatrics
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
Paediatrics

Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors

J Clin Oncol. 2025 Feb 14:JCO2500252. doi: 10.1200/JCO-25-00252. Online ahead of print.

NO ABSTRACT

PMID:39951654 | DOI:10.1200/JCO-25-00252